University of Thessaly (UTH)
Γενετική ανάλυση των πολυμορφισμών στο σύμπλεγμα γονιδίων της IL1 στην IgA νεφροπάθεια
Abstract
dc:descriptionImmunoglobulin A nephropathy (IgAN) is one of the leading causes of end-stage renal disease in developed countries. These can range from no apparent symptoms, such as the presence of asymptomatic hematuria and proteinuria, to gross hematuria accompanied by a rapid decline in kidney function. In the pathophysiology of IgAN a crucial role has been shown for inflammatory cytokines including interleukin-1 (IL-1), a potent mediator with a central role in the inflammatory cascade.Interleukin-1 is involved in mesangial cell proliferation and extracellular matrix production in various glomerulopathies. In cases with IgAN, there is significant glomerular interleukin-1 expression which may be linked to mesangial cell activation in response to nephritogenic immune complexes. Moreover, experimental evidence suggests that in IgAN, interleukin 1 released by mesangial cells could potentially play a role in the development of tubular damage and interstitial fibrosis, both of which are closely associated with the progression of the disease. There are findings that indicate an association between the IL1B and IL1RN genes and heightened vulnerability to IgAN in children Additionally, a connection between the emergence of proteinuria in IgAN and IL1A has been postulated, while IL1B is linked to podocyte foot process effacement. It is reasonable, therefore, to propose that the interleukin 1 gene cluster might have a role in the development and progression of IgA nephropathy. In order to clarify the role of the interleukin-1 complex genes, a genetic association study was performed in which the genotypes for two single-nucleotide polymorphisms, C-899T in the interleukin-1_ gene (IL1A; rs1800587) and C-511T in the interleukin-1_ gene (IL1B; rs16944) were studied. Also one penta-allelic polymorphism with variable numbers of an 86 bp tandem repeat (VNTR *1–*5) in intron 2 of the interleukin-1 receptor antagonist gene (IL1RN). The case-control study consisted of 121 unrelated Caucasians with sporadic, histologically diagnosed IgAN and of 246 age- and sex-matched healthy controls. Persistent proteinuria (>2g/24h) and/or impaired kidney function (serum creatinine>1.5mg/dl) defined progressive (n=67) vs. non-progressive (n=54) IgAN cases. The association of these variants with the susceptibility of IgAN and the development of progressive IgAN (healthy status, IgAN, progressive IgAN) was tested using the generalized odds ratio (ORG) metric. Linkage disequilibrium and haplotype analysis were also performed. In order to clarify the role of interleukins in the development and progression of IgA nephropathy, we synthesized the results of all available GAS which examine the association between variants located in interleukin genes and IgAN. We included in the meta-analysis 15 studies investigating association between 14 interleukin variants harbored in 8 different genes and IgAN. ORG was used to evaluate the association between interleukin variants and IgAN using random effects models. The present case-control study revealed association of IL1B C-511T (rs16944) with the progression of IgAN [p=0.041; ORG=2.11 (1.09-4.07)]. On haplotype analysis, significant results were derived for the haplotypes C-C-1 [p=0.005; OR=0.456 (0.261~0.797)] and C-T-2 [p=0.003; OR=4.208 (1.545-11.50)].Regarding association and meta-analysis results, variants in IL1B (rs1143627, rs16944), IL1RN (rs928940, rs439154 and rs315951) and IL10 (rs1800871) were associated with IgAN. In conclusion genetic variants and haplotypes in the IL1B, IL1RN and IL10 genes might contribute to an increased risk for development and progression of IgAN.
Degree
thesis:*- Grantor dc:publisher
- University of Thessaly (UTH)
- Year dc:date
- 2024
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Chronopoulou, Ioanna
- Χρονοπούλου, Ιωάννα
Subjects
dc:subject × 12Rights
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/56860